GW 468816

DB05417InvestigationalSmall molecule

GW 468816 is glycine receptor antagonist. It is designed to aid abstinence in people who have just quit smoking, delaying the time to relapse. It was undergoing phase II trials...

Primary indication: Investigated for use/treatment in tobacco dependence.Curator reviewed
Code names: GW 468816

Resolves to

Targets

P23416GLRA2O75311GLRA3P48167GLRBP23415GLRA1

What you can answer from here — as of April 23, 2025

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with GW 468816, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account